Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $246

Benzinga Newsdesk www.benzinga.com Positive 85.0%

Neg 0% Neu 0% Pos 85%

Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $242 to $246.